{"id":"carboplatin-etoposide-ifosfamide","safety":{"commonSideEffects":[{"rate":"60-90","effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":"70-90","effect":"Nausea and vomiting"},{"rate":"60-80","effect":"Alopecia"},{"rate":"30-50","effect":"Mucositis"},{"rate":"5-40","effect":"Hemorrhagic cystitis (ifosfamide-related)"},{"rate":"10-30","effect":"Nephrotoxicity"},{"rate":"10-20","effect":"Neurotoxicity"},{"rate":"1-5","effect":"Secondary malignancies"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carboplatin is a platinum-based alkylating agent that forms DNA adducts and cross-links, preventing DNA replication. Ifosfamide is an alkylating agent that similarly damages DNA through cross-linking. Etoposide is a topoisomerase II inhibitor that prevents DNA unwinding and repair. Together, these agents create multiple pathways of DNA damage to kill rapidly dividing cancer cells.","oneSentence":"This combination of three chemotherapy agents works by damaging DNA and preventing cancer cell division through different mechanisms: carboplatin and ifosfamide cross-link DNA strands, while etoposide inhibits topoisomerase II.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:29:47.206Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Germ cell tumors"},{"name":"Small cell lung cancer"},{"name":"Lymphomas"},{"name":"Sarcomas"}]},"trialDetails":[{"nctId":"NCT03418038","phase":"PHASE2","title":"Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2018-03-23","conditions":"Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma","enrollment":80},{"nctId":"NCT05533775","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-11-16","conditions":"Mature B-Cell Non-Hodgkin Lymphoma","enrollment":65},{"nctId":"NCT04663347","phase":"PHASE1, PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":"Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":543},{"nctId":"NCT04486391","phase":"PHASE3","title":"Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"TERMINATED","sponsor":"BeiGene","startDate":"2020-12-14","conditions":"Classical Hodgkin Lymphoma","enrollment":3},{"nctId":"NCT04684368","phase":"PHASE2","title":"A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2021-07-13","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma","enrollment":160},{"nctId":"NCT04322318","phase":"PHASE2","title":"A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2020-10-19","conditions":"Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor","enrollment":256},{"nctId":"NCT05991388","phase":"PHASE2, PHASE3","title":"A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2024-05-02","conditions":"B-cell Non Hodgkin Lymphoma","enrollment":210},{"nctId":"NCT06528496","phase":"PHASE2","title":"N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-07-22","conditions":"High-risk Neuroblastoma, Neuroblastoma, Childhood Neuroblastoma","enrollment":45},{"nctId":"NCT06230224","phase":"PHASE3","title":"A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-02-15","conditions":"B-Cell Non-Hodgkin Lymphoma (B-NHL)","enrollment":216},{"nctId":"NCT01959698","phase":"PHASE1","title":"Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Roswell Park Cancer Institute","startDate":"2014-04-17","conditions":"CD20 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":29},{"nctId":"NCT02106988","phase":"PHASE2","title":"Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-01-16","conditions":"Lymphoma","enrollment":40},{"nctId":"NCT04425070","phase":"PHASE1, PHASE2","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2020-08-18","conditions":"Peripheral T-cell Lymphoma, NK/T-cell Lymphoma","enrollment":56},{"nctId":"NCT06520163","phase":"PHASE3","title":"Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma","status":"RECRUITING","sponsor":"The Affiliated People's Hospital of Ningbo University","startDate":"2024-08-01","conditions":"Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization","enrollment":99},{"nctId":"NCT06333314","phase":"PHASE2","title":"Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI","status":"RECRUITING","sponsor":"UNICANCER","startDate":"2024-07-23","conditions":"Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma","enrollment":120},{"nctId":"NCT05364424","phase":"PHASE1","title":"A Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Glofitamab in Combination With Rituximab Plus Ifosfamide, Carboplatin Etoposide Phosphate in Participants With Relapsed/Refractory Transplant or CAR-T Therapy Eligible Diffuse B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-11-04","conditions":"Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":43},{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT01602666","phase":"PHASE2","title":"Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2012-06-27","conditions":"Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Germinoma","enrollment":262},{"nctId":"NCT05821088","phase":"PHASE2","title":"Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"David Bond, MD","startDate":"2023-06-29","conditions":"Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma","enrollment":37},{"nctId":"NCT02227199","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Washington","startDate":"2014-10-10","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":45},{"nctId":"NCT00077285","phase":"PHASE2","title":"Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2003-10","conditions":"Sarcoma","enrollment":65},{"nctId":"NCT01508312","phase":"PHASE2","title":"Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-01-05","conditions":"Hodgkin's Lymphoma","enrollment":66},{"nctId":"NCT03016871","phase":"PHASE2","title":"Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2017-04-24","conditions":"Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":78},{"nctId":"NCT04833114","phase":"PHASE3","title":"Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GWT-TUD GmbH","startDate":"2021-04-30","conditions":"Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":306},{"nctId":"NCT06905509","phase":"PHASE2","title":"Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Joseph Tuscano","startDate":"2025-07-31","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 Rearrangements","enrollment":25},{"nctId":"NCT07187960","phase":"PHASE3","title":"Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.","startDate":"2025-11","conditions":"Follicular Lymphoma","enrollment":228},{"nctId":"NCT04665765","phase":"PHASE2","title":"Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2021-01-18","conditions":"Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma","enrollment":41},{"nctId":"NCT07081022","phase":"PHASE2","title":"JS203 Combination Regimens in B-Cell Non-Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Shanghai Junshi Bioscience Co., Ltd.","startDate":"2025-08-17","conditions":"B-cell Non-Hodgkin's Lymphoma","enrollment":180},{"nctId":"NCT02393157","phase":"PHASE2","title":"Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL","status":"RECRUITING","sponsor":"New York Medical College","startDate":"2015-08-21","conditions":"Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma","enrollment":25},{"nctId":"NCT04947501","phase":"EARLY_PHASE1","title":"A Study of N9 Chemotherapy in Children With Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-06-22","conditions":"Neuroblastoma, Pediatric Cancer","enrollment":26},{"nctId":"NCT06418789","phase":"PHASE2","title":"High-dose Chemotherapy as Second-line Drug Therapy for Relapsed Germ Cell Tumors","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2024-03-01","conditions":"Germ Cell Tumor","enrollment":25},{"nctId":"NCT02329080","phase":"PHASE2","title":"New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement","status":"COMPLETED","sponsor":"International Extranodal Lymphoma Study Group (IELSG)","startDate":"2014-12","conditions":"Diffuse Large B-cell Lymphoma","enrollment":79},{"nctId":"NCT04221035","phase":"PHASE3","title":"High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2019-11-05","conditions":"High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy","enrollment":800},{"nctId":"NCT04189952","phase":"PHASE2","title":"Acalabrutinib in Combination With R-ICE For Relapsed or Refractory Lymphoma","status":"TERMINATED","sponsor":"University of Miami","startDate":"2020-09-22","conditions":"Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia","enrollment":2},{"nctId":"NCT05705687","phase":"NA","title":"Validation of a Treatment Algorithm for Poor-Risk NSGCTnon Seminomatous Germ-cell Tumors","status":"RECRUITING","sponsor":"Gustave Roussy, Cancer Campus, Grand Paris","startDate":"2023-05-05","conditions":"Non-Seminomatous Germ Cell Tumor","enrollment":150},{"nctId":"NCT04668365","phase":"PHASE2","title":"Zanubrutinib Combined With Standard Chemotherapy in the Treatment for Patients With Diffuse Large B Cell Lymphoma","status":"SUSPENDED","sponsor":"Henan Cancer Hospital","startDate":"2020-12-25","conditions":"Diffuse Large B Cell Lymphoma, CD79A Gene Mutation, CD79B Gene Mutation","enrollment":59},{"nctId":"NCT03440567","phase":"PHASE1","title":"Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2018-04-02","conditions":"Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma","enrollment":16},{"nctId":"NCT04701645","phase":"PHASE1","title":"Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer","status":"RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2022-11-01","conditions":"Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer","enrollment":20},{"nctId":"NCT06792253","phase":"PHASE3","title":"Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"BeBetter Med Inc","startDate":"2025-01-06","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":416},{"nctId":"NCT02375204","phase":"PHASE3","title":"Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2015-08-06","conditions":"Germ Cell Tumor, Teratoma, Choriocarcinoma","enrollment":420},{"nctId":"NCT05221645","phase":"PHASE2","title":"Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southampton","startDate":"2022-06-27","conditions":"Diffuse Large B Cell Lymphoma","enrollment":65},{"nctId":"NCT06669013","phase":"PHASE3","title":"Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas","status":"RECRUITING","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2021-05-20","conditions":"Bone Sarcoma, Embryonal Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma","enrollment":40},{"nctId":"NCT03450343","phase":"PHASE1","title":"Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Medical University of South Carolina","startDate":"2019-04-04","conditions":"Large B-Cell Diffuse Lymphoma","enrollment":9},{"nctId":"NCT05348213","phase":"PHASE2","title":"Novel Targeted Drugs Combined With R-ICE Regimen in Relapsed and Refractory Diffuse Large B-cell Lymphoma","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2022-05-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":76},{"nctId":"NCT06438614","phase":"PHASE2","title":"A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma","status":"COMPLETED","sponsor":"Fundació Sant Joan de Déu","startDate":"2020-08-20","conditions":"Refractory Neuroblastoma, Soft Tissue Cancer","enrollment":47},{"nctId":"NCT00936936","phase":"PHASE2","title":"High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-06-02","conditions":"Testicular Cancer","enrollment":64},{"nctId":"NCT04838652","phase":"PHASE2","title":"Pembrolizumab in Combination With Salvage Chemotherapy for First-relapsed or Refractory Classical Hodgkin Lymphoma","status":"RECRUITING","sponsor":"University of Cologne","startDate":"2024-03-05","conditions":"Classical Hodgkin Lymphoma","enrollment":29},{"nctId":"NCT06552559","phase":"PHASE1, PHASE2","title":"Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2024-05-01","conditions":"B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases","enrollment":37},{"nctId":"NCT06489808","phase":"PHASE2","title":"Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-05-28","conditions":"Relapsed/Refractory Large B-Cell Lymphoma","enrollment":89},{"nctId":"NCT02628405","phase":"PHASE1, PHASE2","title":"R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Academic and Community Cancer Research United","startDate":"2016-05-20","conditions":"Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma","enrollment":30},{"nctId":"NCT02348216","phase":"PHASE1, PHASE2","title":"Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2015-04-21","conditions":"Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL)","enrollment":307},{"nctId":"NCT06321081","phase":"PHASE2","title":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","status":"RECRUITING","sponsor":"Beijing Hospital","startDate":"2024-03-01","conditions":"RAS Mutation, Metastatic Colorectal Cancer, MSS","enrollment":60},{"nctId":"NCT05711628","phase":"PHASE3","title":"A Trial Comparing Chemotherapy Versus Novel Immune Checkpoint Inhibitor (Pembrolizumab) Plus Chemotherapy in Treating Relapsed/Refractory Classical Hodgkin Lymphoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2023-08-10","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":""},{"nctId":"NCT01505569","phase":"NA","title":"Auto Transplant for High Risk or Relapsed Solid or CNS Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2011-10-20","conditions":"Ewing's Family Tumors, Renal Tumors, Hepatoblastoma","enrollment":44},{"nctId":"NCT06263530","phase":"","title":"Prognostic Significance of ctDNA in HL","status":"RECRUITING","sponsor":"Interni hematologicka klinika FNKV","startDate":"2022-01-02","conditions":"Prognostic Cancer Model","enrollment":500},{"nctId":"NCT00007865","phase":"PHASE2","title":"Combination Chemotherapy Plus Rituximab in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2000-09-01","conditions":"Lymphoma","enrollment":""},{"nctId":"NCT06164327","phase":"PHASE1","title":"Study of BEBT-908 Combined With Drugs in the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"UNKNOWN","sponsor":"BeBetter Med Inc","startDate":"2023-12-01","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma","enrollment":75},{"nctId":"NCT02018861","phase":"PHASE1, PHASE2","title":"A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-09-22","conditions":"B-Cell Malignancies","enrollment":88},{"nctId":"NCT01241734","phase":"PHASE1, PHASE2","title":"Study of Lenalidomide in Combination With RICE With Lenalidomide Maintenance Post-Auto Transplant for DLBCL","status":"COMPLETED","sponsor":"Hackensack Meridian Health","startDate":"2010-10","conditions":"Diffuse Large B Cell Lymphoma","enrollment":18},{"nctId":"NCT00788125","phase":"PHASE1, PHASE2","title":"Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors","status":"TERMINATED","sponsor":"City of Hope Medical Center","startDate":"2008-09-03","conditions":"Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor","enrollment":7},{"nctId":"NCT00274924","phase":"PHASE2","title":"Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2006-09-26","conditions":"Lymphoma","enrollment":100},{"nctId":"NCT03077828","phase":"PHASE2","title":"Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"Northwestern University","startDate":"2017-04-21","conditions":"Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma","enrollment":43},{"nctId":"NCT04981899","phase":"PHASE1, PHASE2","title":"A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma","status":"UNKNOWN","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2021-03-01","conditions":"Hodgkin Lymphoma","enrollment":30},{"nctId":"NCT02703272","phase":"PHASE3","title":"A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-07-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":72},{"nctId":"NCT03064867","phase":"PHASE1, PHASE2","title":"Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Molly Gallogly","startDate":"2017-06-26","conditions":"Diffuse Large B-cell-lymphoma","enrollment":65},{"nctId":"NCT01154439","phase":"PHASE1","title":"Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2010-10","conditions":"Leukemia","enrollment":11},{"nctId":"NCT04044222","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of a Sintilimab Plus ICE Regimen Versus ICE Regimen in Classic Hodgkin's Lymphoma Patients (cHL) Who Have Failed First-line Standard Chemotherapy","status":"UNKNOWN","sponsor":"Innovent Biologics (Suzhou) Co. Ltd.","startDate":"2019-10-21","conditions":"Classic Hodgkin's Lymphoma","enrollment":240},{"nctId":"NCT03736616","phase":"PHASE2","title":"Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL","status":"UNKNOWN","sponsor":"Swedish Medical Center","startDate":"2019-08-16","conditions":"Diffuse Large B Cell Lymphoma","enrollment":47},{"nctId":"NCT00712582","phase":"PHASE2","title":"Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2008-07-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":96},{"nctId":"NCT00432094","phase":"PHASE2","title":"Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2006-12-19","conditions":"Childhood Germ Cell Tumor, Ovarian Cancer, Teratoma","enrollment":23},{"nctId":"NCT02471911","phase":"PHASE1","title":"KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma","status":"COMPLETED","sponsor":"Weill Medical College of Cornell University","startDate":"2015-12-11","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":22},{"nctId":"NCT05244642","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Penpulimab in the Relapsed and Refractory Classical Hodgkin's Lymphoma","status":"RECRUITING","sponsor":"Akeso","startDate":"2022-02-15","conditions":"Hodgkin Disease Lymphoma","enrollment":60},{"nctId":"NCT02686346","phase":"PHASE1, PHASE2","title":"Brentuximab Vedotin in Refractory/Relapsed Hodgkin Lymphoma Treated by ICE","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2016-03","conditions":"Hodgkin Disease","enrollment":53},{"nctId":"NCT05124951","phase":"PHASE2","title":"The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2021-09-15","conditions":"Intracranial Germ Cell CNS Tumor, Childhood","enrollment":150},{"nctId":"NCT05050630","phase":"PHASE2","title":"Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL","status":"UNKNOWN","sponsor":"Affiliated Hospital to Academy of Military Medical Sciences","startDate":"2021-08-01","conditions":"Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed","enrollment":73},{"nctId":"NCT00324467","phase":"PHASE2","title":"Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment","status":"UNKNOWN","sponsor":"British Columbia Cancer Agency","startDate":"2006-08","conditions":"Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma","enrollment":150},{"nctId":"NCT03730363","phase":"PHASE1","title":"Pentamidine + Salvage Chemo for Relapsed/Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Reinhold Munker","startDate":"2018-12-19","conditions":"Hodgkin Lymphoma, Refractory Hodgkin Lymphoma","enrollment":1},{"nctId":"NCT03212937","phase":"PHASE1","title":"Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma","status":"COMPLETED","sponsor":"National Cancer Centre, Singapore","startDate":"2016-07-01","conditions":"Peripheral T-cell Lymphoma","enrollment":11},{"nctId":"NCT04860674","phase":"PHASE2","title":"A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma","status":"UNKNOWN","sponsor":"Zhejiang Cancer Hospital","startDate":"2021-05-01","conditions":"Gray Zone Lymphoma, Relapse/Recurrence, Chemotherapy Effect","enrollment":20},{"nctId":"NCT00002566","phase":"PHASE3","title":"Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors","status":"COMPLETED","sponsor":"UNICANCER","startDate":"1994-02","conditions":"Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor","enrollment":280},{"nctId":"NCT00003860","phase":"PHASE2","title":"Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Small Cell Lung Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"1998-09","conditions":"Lung Cancer","enrollment":36},{"nctId":"NCT00864318","phase":"PHASE2","title":"Dose Intensification Study in Refractory Germ Cell Tumors With Relapse and Bad Prognosis","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2009-03-13","conditions":"Germ Cell Tumors","enrollment":101},{"nctId":"NCT01169636","phase":"PHASE1, PHASE2","title":"Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-01-31","conditions":"Hodgkin's Lymphoma","enrollment":62},{"nctId":"NCT02788201","phase":"PHASE2","title":"Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-03-27","conditions":"Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms","enrollment":8},{"nctId":"NCT02445404","phase":"PHASE2","title":"Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-09-23","conditions":"Peripheral T-cell Lymphoma","enrollment":134},{"nctId":"NCT00598169","phase":"PHASE1","title":"Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"AIDS Malignancy Consortium","startDate":"2007-11","conditions":"Lymphoma","enrollment":23},{"nctId":"NCT00345865","phase":"PHASE2","title":"Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2005-08-24","conditions":"Lymphoma","enrollment":473},{"nctId":"NCT00967369","phase":"PHASE2","title":"Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-08-24","conditions":"Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma","enrollment":20},{"nctId":"NCT02638428","phase":"PHASE2","title":"Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2015-12","conditions":"Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML","enrollment":90},{"nctId":"NCT03367143","phase":"PHASE2","title":"Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2016-12","conditions":"Diffuse Large B-Cell Lymphoma Refractory","enrollment":39},{"nctId":"NCT00002974","phase":"PHASE2","title":"Whole-Body Hyperthermia Plus Chemotherapy in Treating Patients With Advanced Sarcoma","status":"COMPLETED","sponsor":"University of Wisconsin, Madison","startDate":"1996-07","conditions":"Sarcoma","enrollment":34},{"nctId":"NCT00137995","phase":"PHASE3","title":"R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma","status":"COMPLETED","sponsor":"Lymphoma Study Association","startDate":"2003-06","conditions":"Lymphoma, Large-Cell, Diffuse","enrollment":481},{"nctId":"NCT03715296","phase":"","title":"Lenalidomide Based Immunotherapy in the Treatment of DLBCL","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2018-10-18","conditions":"Diffuse Large B Cell Lymphoma","enrollment":200},{"nctId":"NCT02137096","phase":"PHASE3","title":"Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma","status":"TERMINATED","sponsor":"University of Florida","startDate":"2014-06","conditions":"Recurrent Nasopharynx Carcinoma","enrollment":1},{"nctId":"NCT02592876","phase":"PHASE2","title":"Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma","status":"TERMINATED","sponsor":"Seagen Inc.","startDate":"2015-10","conditions":"Lymphoma, B-cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Grade 3b","enrollment":81},{"nctId":"NCT01966913","phase":"PHASE1, PHASE2","title":"Salvage Chemotherapy for Poor Prognosis Germ Cell Tumors","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":"Germ Cell Tumor","enrollment":30},{"nctId":"NCT03349346","phase":"PHASE1","title":"Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents","status":"WITHDRAWN","sponsor":"Gilead Sciences","startDate":"2019-06","conditions":"Diffuse Large B-Cell Lymphoma, Mediastinal B-cell Lymphoma","enrollment":""},{"nctId":"NCT01576692","phase":"PHASE1","title":"Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2012-04","conditions":"Neuroblastoma","enrollment":34},{"nctId":"NCT00809341","phase":"PHASE2","title":"R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2009-01","conditions":"Non-Hodgkin's Lymphoma","enrollment":27},{"nctId":"NCT03628131","phase":"PHASE1, PHASE2","title":"Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2018-10","conditions":"Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor","enrollment":46},{"nctId":"NCT01590732","phase":"PHASE1","title":"Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-10-29","conditions":"Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma","enrollment":22}],"_emaApprovals":[],"_faersSignals":[{"count":12,"reaction":"NEUTROPENIA"},{"count":10,"reaction":"CYTOKINE RELEASE SYNDROME"},{"count":10,"reaction":"OFF LABEL USE"},{"count":7,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":6,"reaction":"SEPSIS"},{"count":6,"reaction":"THROMBOCYTOPENIA"},{"count":5,"reaction":"ANAEMIA"},{"count":5,"reaction":"DRUG INEFFECTIVE"},{"count":5,"reaction":"FEBRILE NEUTROPENIA"},{"count":5,"reaction":"ILIUM FRACTURE"}],"_approvalHistory":[],"publicationCount":14,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Carboplatin, Etoposide, Ifosfamide","genericName":"Carboplatin, Etoposide, Ifosfamide","companyName":"University Hospital Muenster","companyId":"university-hospital-muenster","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination of three chemotherapy agents works by damaging DNA and preventing cancer cell division through different mechanisms: carboplatin and ifosfamide cross-link DNA strands, while etoposide inhibits topoisomerase II. Used for Germ cell tumors, Small cell lung cancer, Lymphomas.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}